Clinical trial · Observational
Chemotherapy-Induced Peripheral Neuropathy Survey
Chemotherapy-Induced Peripheral Neuropathy: Feasibility and Validity of New Symptom Measurement Tools in Patients on Treatment With Platinum Agents, Taxanes and Bortezomib
NCT01016028CI-TRIAL-00021995withdrawnClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Study assessment tool development delayed.
Summary
Brief summary (as posted)
The goal of this research study is to learn more about pain and other symptoms that patients may experience while receiving chemotherapy treatment with platinum agents, taxanes, and/or bortezomib.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Chemotherapy-induced Peripheral Neuropathy | — | UNRESOLVED | — |
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| Myeloma | Multiple Myeloma | ALIAS | 0.90 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Interview | Behavioral | — | UNRESOLVED |
| Questionnaire | Behavioral | — | UNRESOLVED |
| Sensory Tests | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Questionnaire + Sensory Tests + Interview
- interventionNames
- Behavioral: Questionnaire
- Behavioral: Sensory Tests
- Behavioral: Interview
Primary outcomes (1)
- measure
- Assessment of Patient's Symptoms (Questionnaire)
- timeFrame
- Each patient administered questionnaire at single point in time.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients \>= 18 years old. 2. Patients must be fluent with the English language. 3. Patients must be on chemotherapy regimes with any of the study drugs: cisplatin, oxaliplatin, taxanes and/or bortezomib. Exclusion Criteria: 1. Significant cognitive impairment as determined by the trained research staff 2. Chronic alcoholism or substance abuse 3. Diagnosis of severe depression
References
Publications (0)
Data not yet available
No reference posted for this study.